Schepens Eye Research Institute of Mass Eye and Ear, Departments of Ophthalmology and Pathology, Harvard Medical School, Boston, Massachusetts, USA.
Department of Immunology, Tufts University School of Medicine, Boston, Massachusetts, USA.
J Clin Invest. 2022 May 2;132(9). doi: 10.1172/JCI158703.
Cardiac repair following ischemic injury is indispensable for survival and requires a coordinated cellular response involving the mobilization of immune cells from the secondary lymphoid organs to the site of damage. Efferocytosis, the engulfment of cell debris and dying cells by innate immune cells, along with lymphangiogenesis, the formation of new lymphatic vessels, are emerging as central to the cardiac healing response. In this issue of the JCI, Glinton et al. used state-of-the-art approaches to demonstrate that efferocytosis induced vascular endothelial growth factor C (VEGFC) in myeloid cells and stimulated lymphangiogenesis and cardiac repair. These findings provide impactful mechanistic information that can be leveraged to therapeutically target pathways in cardiac repair and ischemic heart failure.
缺血性损伤后的心脏修复对于生存是必不可少的,需要一种协调的细胞反应,包括从次级淋巴器官动员免疫细胞到损伤部位。吞噬作用,即先天免疫细胞吞噬细胞碎片和死亡细胞,以及淋巴管生成,即新淋巴管的形成,正成为心脏愈合反应的核心。在本期 JCI 中,Glinton 等人使用最先进的方法证明了吞噬作用诱导髓样细胞中血管内皮生长因子 C(VEGFC),并刺激了淋巴管生成和心脏修复。这些发现提供了有影响力的机制信息,可以用于治疗性靶向心脏修复和缺血性心力衰竭的途径。